uniQure (QURE) to Release Earnings on Wednesday

uniQure (NASDAQ:QURE) is expected to be issuing its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to announce earnings of ($0.8223) per share and revenue of $5.4490 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. On average, analysts expect uniQure to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

uniQure Stock Down 5.0%

Shares of uniQure stock traded down $1.92 during trading on Tuesday, reaching $36.30. The stock had a trading volume of 558,568 shares, compared to its average volume of 2,554,861. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $2.29 billion, a price-to-earnings ratio of -10.43 and a beta of 0.90. The stock has a fifty day moving average price of $36.20 and a two-hundred day moving average price of $25.80. uniQure has a 52 week low of $8.73 and a 52 week high of $71.50.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. HC Wainwright lifted their target price on uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Stifel Nicolaus set a $28.00 price target on uniQure in a research report on Tuesday, May 5th. Barclays raised shares of uniQure from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $25.00 to $65.00 in a research note on Thursday, June 18th. The Goldman Sachs Group lifted their price objective on shares of uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, June 18th. Finally, Leerink Partners boosted their price objective on shares of uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Twelve analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and a consensus price target of $64.17.

Insider Activity

In other news, Director Madhavan Balachandran sold 11,685 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total value of $526,526.10. Following the completion of the sale, the director directly owned 43,254 shares of the company’s stock, valued at $1,949,025.24. This trade represents a 21.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew C. Kapusta sold 21,082 shares of uniQure stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $45.16, for a total value of $952,063.12. Following the transaction, the chief executive officer owned 519,227 shares of the company’s stock, valued at $23,448,291.32. This represents a 3.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 433,229 shares of company stock valued at $17,944,799. Company insiders own 4.65% of the company’s stock.

Institutional Investors Weigh In On uniQure

A number of large investors have recently added to or reduced their stakes in QURE. Virtus Investment Advisers LLC boosted its position in uniQure by 91.6% during the fourth quarter. Virtus Investment Advisers LLC now owns 13,636 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 6,520 shares during the period. SummitTX Capital L.P. lifted its stake in shares of uniQure by 386.3% during the 4th quarter. SummitTX Capital L.P. now owns 27,708 shares of the biotechnology company’s stock worth $663,000 after buying an additional 22,010 shares during the last quarter. Suvretta Capital Management LLC acquired a new stake in shares of uniQure during the 4th quarter worth about $29,116,000. Readystate Asset Management LP bought a new stake in shares of uniQure during the 4th quarter worth about $8,652,000. Finally, Orbimed Advisors LLC boosted its holdings in shares of uniQure by 60.8% during the 4th quarter. Orbimed Advisors LLC now owns 737,400 shares of the biotechnology company’s stock worth $17,646,000 after buying an additional 278,900 shares during the period. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.